Author

A. L. Hong

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Approach:statistical model· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Assay:whole-exome sequencing· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

B. D. Kynnap· 2 shared C. M. Clinton· 2 shared D. E. Root· 2 shared E. A. Mullen· 2 shared J. Farhi· 2 shared J. M. Spangle· 2 shared J. S. Boehm· 2 shared K. L. Ligon· 2 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. D. Kynnap

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Histone H3 E50K mutation confers oncogenic activity and supports an EMT phenotype

K. Sad, C. Y. Jones, D. V. Fawwal, E. J. Hill, K. Skinner, S. Lustenberger, R. S. Lee, S. R. Elayavalli, J. Farhi, L. D. Lemon, M. B. Fasken, A. L. Hong, S. A. Sloan, A. H. Corbett, J. M. Spangle

This paper shows that the H3E50K mutation in histone H3 promotes oncogenic activity by enhancing cell migration, invasion, and epithelial-mesenchymal transition.

bioRxiv · Oct 11, 2023 · PreprintCancer Biology

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

K. Mittal, B. P. Lee, G. W. Cooper, J. Shim, H. C. Jonus, W. J. Kim, M. Doshi, D. Almanza, B. D. Kynnap, A. L. Christie, X. Yang, G. S. Cowley, B. A. Leeper, C. L. Morton, B. Dwivedi, , A. L. Hong

This study identifies XPO1 inhibition with selinexor as a potential therapy for favorable histology Wilms tumors, showing synergy with doxorubicin in preclinical models.

bioRxiv · Feb 23, 2022Cancer Biology

Targeting MLL methyltransferases enhance the anti-tumor effects of PI3K inhibition in hormone receptor-positive breast cancer

R. B. Jones, J. Farhi, M. Adams, K. Parwani, M. Zecevic, G. Cooper, R. S. Lee, A. L. Hong, J. Spangle

This paper shows that combining PI3K and MLL1 inhibition enhances anti-tumor effects in HR+ breast cancer by disrupting a feedback loop between MLL1 and AKT.

bioRxiv · Oct 1, 2021Cancer Biology

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

A. L. Hong, Y.-Y. Tseng, J. A. Wala, W. J. Kim, B. D. Kynnap, M. B. Doshi, G. Kugener, G. J. Sandoval, T. P. Howard, J. Li, X. Yang, M. Tillgren, M. Ghandi, A. Sayeed, R. Deasy, , W. Hahn

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.

bioRxiv · Dec 5, 2018Cancer Biology